Company: PACB
Filing Date: 2025-03-17
Form Type: 10-K
Source: 0001299130-25-000061
Chunk: 978

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-03-17
Form: 10-K
Item: Item 8
Chunk 978
---
219 Accumulated deficit (2,148,926)(1,839,075)Total stockholders’ equity 506,594 701,304 Total liabilities and stockholders’ equity $1,260,447 $1,746,013 

See accompanying notes to the consolidated financial statements. 

Fiscal 2024 Form 10-K85

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

Years Ended December 31,(in thousands, except per share amounts)202420232022Revenue:Product revenue $136,149 $183,872 $108,699 Service and other revenue 17,865 16,649 19,605 Total revenue 154,014 200,521 128,304 Cost of Revenue:Cost of product revenue 92,284 127,568 60,932 Cost of service and other revenue 14,057 14,754 13,899 Amortization of acquired intangible assets9,393 1,983 733 Loss on purchase commitment998 3,436 3,705 Total cost of revenue 116,732 147,741 79,269 Gross profit 37,282 52,780 49,035 Operating Expense:Research and development 134,922 187,170 193,000 Sales, general and administrative 175,017 169,818 160,854 Impairment charges184,500 — — Merger-related expenses— 9,042 — Change in fair value of contingent consideration(850)15,060 2,377 Amortization of acquired intangible assets18,006 6,157 — Total operating expense 511,595 387,247 356,231 Operating loss (474,313)(334,467)(307,196)Loss on extinguishment of debt— (2,033)— Gain on debt restructuring154,407 — — Interest expense (13,412)(14,343)(14,690)Other income, net 23,783 32,684 7,638 Loss before income taxes(309,535)(318,159)(314,248)Income tax provision (benefit)316 (11,424)— Net loss(309,851)(306,735)(314,248